Apricus Biosciences has submitted marketing application with Swissmedic - the Swiss agency for therapeutic products - to market Vitaros for the treatment of patients with erectile dysfunction (ED) in Switzerland.
Unlike Viagra, Cialis and Levitra, Vitaros is applied directly to the penis as a cream.
Vitaros contains a previously marketed ED drug - alprostadil.
When absorbed through the skin, alprostadil directly boosts blood flow, thereby causing an erection within minutes.
Apricus chairman, president and CEO Bassam Damaj said they are excited about making their third major filing for their product, Vitaros for the treatment of ED.
"We look forward to applying for approval for this product and for the ED indication in other important international markets in the future," Damaj said.
Share:
No comments:
Post a Comment